{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T02:13:22Z","timestamp":1792548802052,"version":"4.5.0"},"reference-count":140,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T00:00:00Z","timestamp":1714003200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Psoriasis is a highly prevalent dermatological disease associated with an increased systemic inflammatory response. In addition, joint involvement is also present in around 20% of patients. Therefore, treatment modalities used in this condition should be simultaneously effective at improving skin manifestations, reducing inflammation, and addressing psoriatic arthritis when present. Twenty years ago, the introduction of biologic treatments for psoriasis was a turning point in the management of this condition, offering an effective and reasonably safe option for patients whose disease could not be adequately controlled with conventional therapies. At the moment, Janus Kinase inhibitors (JAKis) are a new class of promising molecules in the management of psoriasis. They are orally administered and can show benefits in patients who failed biologic therapy. We conducted a scoping review in order to identify randomized-controlled trials that investigated different JAKis in patients with plaque psoriasis and psoriatic arthritis, with an emphasis on molecules that have been approved by the European Medicines Agency and the Food and Drug Administration. The added value of this study is that it collected information about JAKis approved for two different indications, plaque psoriasis and psoriatic arthritis, in order to provide an integrated understanding of the range of effects that JAKis have on the whole spectrum of psoriasis manifestations.<\/jats:p>","DOI":"10.3390\/ijms25094681","type":"journal-article","created":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T05:13:41Z","timestamp":1714108421000},"page":"4681","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Inhibition of the JAK-STAT Pathway in the Treatment of Psoriasis: A Review of the Literature"],"prefix":"10.3390","volume":"25","author":[{"given":"Andreea Roxana","family":"Furtunescu","sequence":"first","affiliation":[{"name":"Department of Dermatology, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 020021 Bucharest, Romania"},{"name":"Department of Dermatology, \u201cVictor Babes\u201d Clinical Hospital for Infectious Diseases, 030303 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona Roxana","family":"Georgescu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 020021 Bucharest, Romania"},{"name":"Department of Dermatology, \u201cVictor Babes\u201d Clinical Hospital for Infectious Diseases, 030303 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4983-7648","authenticated-orcid":false,"given":"Mircea","family":"Tampa","sequence":"additional","affiliation":[{"name":"Department of Dermatology, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 020021 Bucharest, Romania"},{"name":"Department of Dermatology, \u201cVictor Babes\u201d Clinical Hospital for Infectious Diseases, 030303 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Matei","sequence":"additional","affiliation":[{"name":"Department of Dermatology, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 020021 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,4,25]]},"reference":[{"key":"ref_1","unstructured":"Michalek, I.M., Loring, B., John, S.M., and World Health Organization (2016). Global Report on Psoriasis, World Health Organization."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"m1590","DOI":"10.1136\/bmj.m1590","article-title":"National, regional, and worldwide epidemiology of psoriasis: Systematic analysis and modelling study","volume":"369","author":"Parisi","year":"2020","journal-title":"BMJ"},{"key":"ref_3","unstructured":"Prevalence Heat Map (2024, March 03). Global Psoriasis Atlas. Available online: https:\/\/www.globalpsoriasisatlas.org\/en\/explore\/prevalence-heatmap."},{"key":"ref_4","unstructured":"Meyer, A., Kirveskoski, H., Melancia, J., Koukopoulou, T., Sutton, P., and van de Kerkhof, P.C. (2022). Briefing Book: IFPA Forum 2022, International Federation of Psoriatic Disease Associations."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1080\/08820139.2024.2302823","article-title":"Etiopathogenesis of Psoriasis: Integration of Proposed Theories","volume":"53","year":"2024","journal-title":"Immunol. Investig."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1093\/rheumatology\/kes324","article-title":"Prevalence and treatment patterns of psoriatic arthritis in the UK","volume":"52","author":"Ogdie","year":"2013","journal-title":"Rheumatology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1111\/j.1468-3083.2011.03985.x","article-title":"Prevalence and characteristics of psoriatic arthritis in Chinese patients with psoriasis","volume":"25","author":"Yang","year":"2011","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1590\/S0365-05962012000400003","article-title":"Psoriatic arthritis in patients with psoriasis: Evaluation of clinical and epidemiological features in 133 patients followed at the University Hospital of Bras\u00edlia","volume":"87","author":"Carneiro","year":"2012","journal-title":"An. Bras. Dermatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1002\/art.24608","article-title":"The prevalence of psoriatic arthritis in people with psoriasis","volume":"61","author":"Ibrahim","year":"2009","journal-title":"Arthritis Care Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.jaad.2014.05.010","article-title":"Comparative performance of psoriatic arthritis screening tools in patients with psoriasis in European\/North American dermatology clinics","volume":"71","author":"Mease","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jaad.2018.06.027","article-title":"Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies","volume":"80","author":"Alinaghi","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"103202","DOI":"10.1016\/j.jaut.2024.103202","article-title":"Global and regional epidemiology of psoriatic arthritis in patients with psoriasis: A comprehensive systematic analysis and modelling study","volume":"145","author":"Kang","year":"2024","journal-title":"J. Autoimmun."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1517\/13543784.9.7.1511","article-title":"Psoriatic arthritis","volume":"9","author":"Gladman","year":"2000","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1093\/eurheartj\/ehr285","article-title":"Psoriasis and risk of atrial fibrillation and ischaemic stroke: A Danish Nationwide Cohort Study","volume":"33","author":"Ahlehoff","year":"2012","journal-title":"Eur. Heart J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.amjcard.2011.11.025","article-title":"Coronary Artery Disease in Patients with Psoriasis Referred for Coronary Angiography","volume":"109","author":"Armstrong","year":"2012","journal-title":"Am. J. Cardiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s13555-024-01126-y","article-title":"A Prospective, Monocentric Case-Control Study on Uncontrolled Psoriasis as Independent Risk Factor for a Hypercoagulable State","volume":"14","author":"Hillary","year":"2024","journal-title":"Dermatol. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1684\/ejd.2023.4585","article-title":"Psoriasis in Norway: A prescription-based registry study of psoriasis-associated comorbidities","volume":"33","author":"Solberg","year":"2023","journal-title":"Eur. J. Dermatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.296.14.1735","article-title":"Risk of Myocardial Infarction in Patients with Psoriasis","volume":"296","author":"Gelfand","year":"2006","journal-title":"JAMA"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1038\/jid.2010.103","article-title":"Psoriasis and Systemic Inflammatory Diseases: Potential Mechanistic Links between Skin Disease and Co-Morbid Conditions","volume":"130","author":"Davidovici","year":"2010","journal-title":"J. Investig. Dermatol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Blauvelt, A., and Chiricozzi, A. (2018). The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis. Clinical Reviews in Allergy and Immunology, Humana Press Inc.","DOI":"10.1007\/s12016-018-8702-3"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nrrheum.2015.53","article-title":"The IL-23-IL-17 axis in inflammatory arthritis","volume":"11","author":"Lubberts","year":"2015","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1016\/S0140-6736(18)30830-4","article-title":"The pathogenesis of psoriatic arthritis","volume":"391","author":"Veale","year":"2018","journal-title":"Lancet"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"ref_24","first-page":"249","article-title":"Evaluation of the sexual sphere in patients with psoriatic arthritis","volume":"19","year":"2023","journal-title":"Reumatol. Cl\u00ednica"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1111\/1346-8138.16941","article-title":"Association of psoriasis with depression, anxiety, and suicidality: A bidirectional two-sample Mendelian randomization study","volume":"50","author":"Chu","year":"2023","journal-title":"J. Dermatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1016\/j.jid.2023.05.007","article-title":"Itch Is More Important than Clinical Disease Severity for Depression in Psoriasis: A Prospective Register Study","volume":"143","author":"Svedbom","year":"2023","journal-title":"J. Investig. Dermatol."},{"key":"ref_27","first-page":"e51968","article-title":"A Patient Survey Exploring the Burden of Inflammatory Back Pain in Patients with Known Psoriasis","volume":"16","author":"Watts","year":"2024","journal-title":"Cureus"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Nymand, L., Kristensen, L.E., Thomsen, S.F., Thyssen, J.P., and Egeberg, A. (2024). Characteristics and drivers of fatigue in patients with psoriasis and psoriatic arthritis: A cross sectional study. J. Am. Acad. Dermatol., in press.","DOI":"10.1016\/j.jaad.2024.02.026"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13075-024-03282-0","article-title":"Improvement in work productivity among psoriatic arthritis patients treated with biologic or targeted synthetic drugs: A systematic literature review and meta-analysis","volume":"26","author":"Gossec","year":"2024","journal-title":"Arthritis Res. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1080\/1744666X.2018.1468252","article-title":"Quality of life in psoriatic arthritis","volume":"14","author":"Gudu","year":"2018","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): Updated treatment recommendations for psoriatic arthritis 2021","volume":"18","author":"Coates","year":"2022","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update","volume":"79","author":"Gossec","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1468-3083.2009.03389.x","article-title":"European S3-Guidelines on the systemic treatment of psoriasis vulgaris","volume":"23","author":"Pathirana","year":"2009","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s13555-022-00846-3","article-title":"Elevating the Standard of Care for Patients with Psoriasis: \u2018Calls to Action\u2019 from Epicensus, a Multistakeholder Pan-European Initiative","volume":"13","author":"Koren","year":"2023","journal-title":"Dermatol. Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1111\/jdv.19191","article-title":"Statins and psoriasis: Position statement by the Psoriasis Task Force of the European Academy of Dermatology and Venerology","volume":"37","author":"Boehncke","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJM199707173370301","article-title":"Treatment of Rheumatoid Arthritis with a Recombinant Human Tumor Necrosis Factor Receptor (p75)\u2013Fc Fusion Protein","volume":"337","author":"Moreland","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Kamata, M., and Tada, Y. (2020). Efficacy and Safety of Biologics for Psoriasis and Psoriatic Arthritis and Their Impact on Comorbidities: A Literature Review. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21051690"},{"key":"ref_38","unstructured":"Bolognia, J.L., Jorizzo, J.J., Schaffer, J.V., Callen, J.P., Cerroni, L., Heymann, W.R., Hruza, G.J., Mancini, A.J., McGrath, J., and Patterson, J.W. (2018). Dermatology, Elsevier."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1080\/17512433.2020.1767590","article-title":"Switching biologics in psoriasis\u2014Practical guidance and evidence to support","volume":"13","author":"Tsai","year":"2020","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00403-018-1808-x","article-title":"Treatment preferences and treatment satisfaction among psoriasis patients: A systematic review","volume":"310","author":"Florek","year":"2018","journal-title":"Arch. Dermatol. Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2147\/PPA.S121838","article-title":"Evaluation of psoriasis patients\u2019 attitudes toward benefit-risk and therapeutic trade-offs in their choice of treatments","volume":"11","author":"Eliasson","year":"2017","journal-title":"Patient Prefer. Adherence"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ijpharm.2016.02.014","article-title":"Gastrointestinal stability of therapeutic anti-TNF \u03b1 IgG1 monoclonal antibodies","volume":"502","author":"Yadav","year":"2016","journal-title":"Int. J. Pharm."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Carmona-Rocha, E., Rusi\u00f1ol, L., and Puig, L. (2024). New and Emerging Oral\/Topical Small-Molecule Treatments for Psoriasis. Pharmaceutics, 16.","DOI":"10.20944\/preprints202401.0800.v1"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1136\/ard-2023-223850","article-title":"Selectivity, efficacy and safety of JAKinibs: New evidence for a still evolving story","volume":"83","author":"Bonelli","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/annrheumdis-2020-218398","article-title":"Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: A consensus statement","volume":"80","author":"Nash","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.abd.2023.03.001","article-title":"JAK-STAT pathway inhibitors in dermatology","volume":"98","author":"Miot","year":"2023","journal-title":"An. Bras. Dermatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","article-title":"The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention","volume":"66","author":"Schwartz","year":"2015","journal-title":"Annu. Rev. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nrd.2017.201","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"16","author":"Schwartz","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1093\/ced\/llad188","article-title":"Emerging role of topical Janus kinase inhibitors in dermatological disorders: A review","volume":"48","author":"Dogra","year":"2023","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/j.1365-2567.2011.03522.x","article-title":"Interleukin-23: As a drug target for autoimmune inflammatory diseases","volume":"135","author":"Tang","year":"2012","journal-title":"Immunology"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1684\/ejd.2015.2663","article-title":"Topical therapy for psoriasis: A promising future. Focus on JAK and phosphodiesterase-4 inhibitors","volume":"26","author":"Rafael","year":"2016","journal-title":"Eur. J. Dermatol."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"S\u0142uczanowska-G\u0142\u0105bowska, S., Ziegler-Krawczyk, A., Szumilas, K., and Pawlik, A. (2021). Role of Janus Kinase Inhibitors in Therapy of Psoriasis. J. Clin. Med., 10.","DOI":"10.3390\/jcm10194307"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1084\/jem.181.1.399","article-title":"Interleukin 12 (IL-12) induces tyrosine phosphorylation of JAK2 and TYK2: Differential use of Janus family tyrosine kinases by IL-2 and IL-12","volume":"181","author":"Bacon","year":"1995","journal-title":"J. Exp. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1111\/bjd.12517","article-title":"Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment","volume":"169","author":"Strober","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.immuni.2012.03.014","article-title":"JAK and STAT Signaling Molecules in Immunoregulation and Immune-Mediated Disease","volume":"36","author":"Plenge","year":"2012","journal-title":"Immunity"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.4049\/jimmunol.1003668","article-title":"Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)","volume":"186","author":"Ghoreschi","year":"2011","journal-title":"J. Immunol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"410","DOI":"10.5455\/medarh.2018.72.410-413","article-title":"Serum Concentrations of Interferon Gamma (IFN- and #947;) in Patients with Psoriasis: Correlation with Clinical Type and Severity of the Disease","volume":"72","author":"Kurtovic","year":"2018","journal-title":"Med. Arch."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s13555-021-00596-8","article-title":"Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1\/2\/3 Inhibitors","volume":"11","author":"Chimalakonda","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e00537","DOI":"10.1002\/prp2.537","article-title":"Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition","volume":"7","author":"Dowty","year":"2019","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.immuni.2004.07.007","article-title":"IL-22 Increases the Innate Immunity of Tissues","volume":"21","author":"Wolk","year":"2004","journal-title":"Immunity"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/s41392-023-01655-6","article-title":"Signaling pathways and targeted therapies for psoriasis","volume":"8","author":"Guo","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"eaaw1736","DOI":"10.1126\/scitranslmed.aaw1736","article-title":"Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain","volume":"11","author":"Burke","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"ref_63","first-page":"ii67","article-title":"Targeting the Jak\/STAT pathway for immunosuppression","volume":"63","year":"2004","journal-title":"Ann. Rheum. Dis."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1111\/jdv.14433","article-title":"The role of IL-23 and the IL-23\/Th17 immune axis in the pathogenesis and treatment of psoriasis","volume":"31","author":"Girolomoni","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1084\/jem.181.5.1755","article-title":"Interleukin 12 signaling in T helper type 1 (Th1) cells involves tyrosine phosphorylation of signal transducer and activator of transcription (Stat)3 and Stat4","volume":"181","author":"Jacobson","year":"1995","journal-title":"J. Exp. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.0105-2896.2004.00211.x","article-title":"Signaling by IL-12 and IL-23 and the immunoregulatory roles of STAT4","volume":"202","author":"Watford","year":"2004","journal-title":"Immunol. Rev."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1084\/jem.184.2.747","article-title":"Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation","volume":"184","author":"Cella","year":"1996","journal-title":"J. Exp. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1365-2567.2008.03017.x","article-title":"Interleukin-17 in host defence against bacterial, mycobacterial and fungal pathogens","volume":"126","author":"Curtis","year":"2009","journal-title":"Immunology"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1038\/jid.2008.85","article-title":"T-Helper 17 Cells in Psoriatic Plaques and Additional Genetic Links between IL-23 and Psoriasis","volume":"128","author":"Blauvelt","year":"2008","journal-title":"J. Investig. Dermatol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2147\/PTT.S323300","article-title":"Reducing the Risk of Developing Psoriatic Arthritis in Patients with Psoriasis","volume":"12","author":"Gisondi","year":"2022","journal-title":"Psoriasis Targets Ther."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"381","DOI":"10.4103\/ijd.ijd_571_22","article-title":"Psoriatic Arthritis: A Comprehensive Update for Dermatologists with Review of Literature","volume":"67","author":"Datta","year":"2022","journal-title":"Indian J. Dermatol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/j.1365-2133.2012.11168.x","article-title":"Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: A Phase 2b randomized placebo-controlled dose-ranging study","volume":"167","author":"Papp","year":"2012","journal-title":"Br. J. Dermatol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1476-9255-7-41","article-title":"Anti-inflammatory activity and neutrophil reductions mediated by the JAK1\/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis","volume":"7","author":"Meyer","year":"2010","journal-title":"J. Inflamm."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41584-021-00726-8","article-title":"Janus kinase-targeting therapies in rheumatology: A mechanisms-based approach","volume":"18","author":"Tanaka","year":"2022","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1111\/bjd.13551","article-title":"Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: A randomized controlled trial","volume":"172","author":"Bissonnette","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0140-6736(14)62113-9","article-title":"Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: A phase 3 randomised non-inferiority trial","volume":"386","author":"Bachelez","year":"2015","journal-title":"Lancet"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/bjd.14018","article-title":"Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Results from two randomized, placebo-controlled, phase III trials","volume":"173","author":"Papp","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jdermsci.2017.05.004","article-title":"The efficacy and safety of tofacitinib in Asian patients with moderate to severe chronic plaque psoriasis: A Phase 3, randomized, double-blind, placebo-controlled study","volume":"88","author":"Zhang","year":"2017","journal-title":"J. Dermatol. Sci."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","article-title":"Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors","volume":"377","author":"Gladman","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","article-title":"Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis","volume":"377","author":"Mease","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"e002559","DOI":"10.1136\/rmdopen-2022-002559","article-title":"Efficacy and safety of tofacitinib in Chinese patients with active psoriatic arthritis: A phase 3, randomised, double-blind, placebo-controlled study","volume":"9","author":"Leng","year":"2023","journal-title":"RMD Open"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.jaci.2015.12.1318","article-title":"Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: A randomized phase 2 study","volume":"137","author":"Krueger","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_83","first-page":"252","article-title":"Efficacy of tofacitinib, an oral janus kinase inhibitor, on clinical signs of moderate-to- severe plaque psoriasis in different body regions","volume":"13","author":"Menter","year":"2014","journal-title":"J. Drugs Dermatol."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Valenzuela, F., Papp, K.A., Pariser, D., Tyring, S.K., Wolk, R., Buonanno, M., Wang, J., Tan, H., and Valdez, H. (2015). Effects of tofacitinib on lymphocyte sub-populations, CMV and EBV viral load in patients with plaque psoriasis. BMC Dermatol., 15.","DOI":"10.1186\/s12895-015-0025-y"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/bjd.16004","article-title":"Efficacy and safety of the Janus kinase 1 inhibitor PF-04965842 in patients with moderate-to-severe psoriasis: Phase II, randomized, double-blind, placebo-controlled study","volume":"179","author":"Schmieder","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/jdv.12081","article-title":"Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis","volume":"28","author":"Mamolo","year":"2014","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3109\/09546634.2013.861891","article-title":"The relationship between pruritus and the clinical signs of psoriasis in patients receiving tofacitinib","volume":"26","author":"Bushmakin","year":"2015","journal-title":"J. Dermatol. Treat."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/jdv.13808","article-title":"Effect of tofacitinib withdrawal and re-treatment on patient-reported outcomes: Results from a Phase 3 study in patients with moderate to severe chronic plaque psoriasis","volume":"31","author":"Griffiths","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1111\/jdv.13702","article-title":"Tofacitinib versus etanercept or placebo in patients with moderate to severe chronic plaque psoriasis: Patient-reported outcomes from a Phase 3 study","volume":"30","author":"Paul","year":"2016","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jid.2017.08.040","article-title":"Reduction of Inflammatory and Cardiovascular Proteins in the Blood of Patients with Psoriasis: Differential Responses between Tofacitinib and Etanercept after 4 Weeks of Treatment","volume":"138","author":"Kim","year":"2018","journal-title":"J. Investig. Dermatol."},{"key":"ref_91","first-page":"568","article-title":"Efficacy of Tofacitinib for the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis in Patient Subgroups from Two Randomised Phase 3 Trials","volume":"15","author":"Menter","year":"2016","journal-title":"J. Drugs Dermatol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/09546634.2016.1214671","article-title":"Early clinical response to tofacitinib treatment as a predictor of subsequent efficacy: Results from two phase 3 studies of patients with moderate-to-severe plaque psoriasis","volume":"28","author":"Tan","year":"2017","journal-title":"J. Dermatol. Treat."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jaad.2017.01.053","article-title":"Efficacy of tofacitinib for the treatment of nail psoriasis: Two 52-week, randomized, controlled phase 3 studies in patients with moderate-to-severe plaque psoriasis","volume":"77","author":"Merola","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1111\/1346-8138.13956","article-title":"Tofacitinib for the treatment of moderate to severe chronic plaque psoriasis in Japanese patients: Subgroup analyses from a randomized, placebo-controlled phase 3 trial","volume":"44","author":"Abe","year":"2017","journal-title":"J. Dermatol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/1346-8138.13258","article-title":"Oral tofacitinib efficacy, safety and tolerability in Japanese patients with moderate to severe plaque psoriasis and psoriatic arthritis: A randomized, double-blind, phase 3 study","volume":"43","author":"Asahina","year":"2016","journal-title":"J. Dermatol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"e000806","DOI":"10.1136\/rmdopen-2018-000806","article-title":"Tofacitinib or adalimumab versus placebo: Patient-reported outcomes from OPAL Broaden\u2014A phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs","volume":"5","author":"Strand","year":"2019","journal-title":"RMD Open"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.3899\/jrheum.180971","article-title":"Radiographic progression according to baseline C-reactive protein levels and other risk factors in psoriatic arthritis treated with tofacitinib or adalimumab","volume":"46","author":"Gladman","year":"2019","journal-title":"J. Rheumatol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"e000808","DOI":"10.1136\/rmdopen-2018-000808","article-title":"Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL beyond","volume":"5","author":"Strand","year":"2019","journal-title":"RMD Open"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e001486","DOI":"10.1136\/rmdopen-2020-001486","article-title":"Impact of baseline body mass index on the efficacy and safety of tofacitinib in patients with psoriatic arthritis","volume":"7","author":"Giles","year":"2021","journal-title":"RMD Open"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1007\/s40265-022-01796-y","article-title":"Deucravacitinib: First Approval","volume":"82","author":"Hoy","year":"2022","journal-title":"Drugs"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/cts.13435","article-title":"First-in-human study of deucravacitinib: A selective, potent, allosteric small-molecule inhibitor of tyrosine kinase 2","volume":"16","author":"Catlett","year":"2023","journal-title":"Clin. Transl. Sci."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJMoa1806382","article-title":"Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis","volume":"379","author":"Papp","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial","volume":"88","author":"Armstrong","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jaad.2022.08.061","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial","volume":"88","author":"Strober","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/annrheumdis-2021-221664","article-title":"Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis","volume":"81","author":"Mease","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/bjd\/ljae014","article-title":"Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials","volume":"190","author":"Lebwohl","year":"2024","journal-title":"Br. J. Dermatol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"e13688","DOI":"10.1111\/cts.13688","article-title":"Upadacitinib: Mechanism of action, clinical, and translational science","volume":"17","author":"Mohamed","year":"2024","journal-title":"Clin. Transl. Sci."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"e001838","DOI":"10.1136\/rmdopen-2021-001838","article-title":"Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study","volume":"7","author":"McInnes","year":"2021","journal-title":"RMD Open"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1136\/annrheumdis-2020-218870","article-title":"Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2","volume":"80","author":"Mease","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_110","first-page":"275","article-title":"Efficacy and Safety of Upadacitinib in Patients with Psoriatic Arthritis: 2-Year Results from the Phase 3 SELECT-PsA 1 Study","volume":"10","author":"McInnes","year":"2023","journal-title":"Rheumatol. Ther."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s40744-021-00305-z","article-title":"Upadacitinib in Patients with Psoriatic Arthritis and Inadequate Response to Biologics: 56-Week Data from the Randomized Controlled Phase 3 SELECT-PsA 2 Study","volume":"8","author":"Mease","year":"2021","journal-title":"Rheumatol. Ther."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13075-023-03027-5","article-title":"Efficacy and safety of upadacitinib in patients with active psoriatic arthritis and axial involvement: Results from two phase 3 studies","volume":"25","author":"Baraliakos","year":"2023","journal-title":"Arthritis Res. Ther."},{"key":"ref_113","first-page":"2286","article-title":"Upadacitinib in patients with psoriatic arthritis and inadequate response to biologics: 3-year results from the open-label extension of the randomised controlled phase 3 SELECT-PsA 2 study","volume":"41","author":"Mease","year":"2023","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1111\/bjd.14403","article-title":"A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1\/JAK2 inhibitor, in patients with moderate-to-severe psoriasis","volume":"174","author":"Papp","year":"2016","journal-title":"Br. J. Dermatol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1016\/j.jid.2020.03.962","article-title":"TYK2\/JAK1 Inhibitor PF-06700841 in Patients with Plaque Psoriasis: Phase IIa, Randomized, Double-Blind, Placebo-Controlled Trial","volume":"140","author":"Forman","year":"2020","journal-title":"J. Investig. Dermatol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1002\/art.42519","article-title":"Efficacy and Safety of the TYK2\/JAK1 Inhibitor Brepocitinib for Active Psoriatic Arthritis: A Phase IIb Randomized Controlled Trial","volume":"75","author":"Mease","year":"2023","journal-title":"Arthritis Rheumatol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1016\/S0140-6736(18)32483-8","article-title":"Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): Results from a randomised, placebo-controlled, phase 2 trial","volume":"392","author":"Mease","year":"2018","journal-title":"Lancet"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1016\/S2352-3026(21)00367-7","article-title":"Efficacy and safety of itacitinib versus placebo in combination with corticosteroids for initial treatment of acute graft-versus-host disease (GRAVITAS-301): A randomised, multicentre, double-blind, phase 3 trial","volume":"9","author":"Zeiser","year":"2022","journal-title":"Lancet Haematol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"332","DOI":"10.3109\/09546634.2015.1115819","article-title":"A randomized, double-blind, placebo-controlled, dose-escalation study of the safety and efficacy of INCB039110, an oral janus kinase 1 inhibitor, in patients with stable, chronic plaque psoriasis","volume":"27","author":"Bissonnette","year":"2016","journal-title":"J. Dermatol. Treat."},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Tanaka, Y., Takeuchi, T., Morita, Y., Kaneko, Y., and Terada, W. (2023). Safety and effectiveness of peficitinib 100\u2009mg\/day in patients achieving clinical remission from a long-term open-label extension study in Japan, Korea, and Taiwan (RAJ2). Mod. Rheumatol., road110.","DOI":"10.1093\/mr\/road110"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/bjd.13745","article-title":"A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis","volume":"173","author":"Papp","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jaad.2022.03.059","article-title":"Oral tyrosine kinase 2 inhibitor PF-06826647 demonstrates efficacy and an acceptable safety profile in participants with moderate-to-severe plaque psoriasis in a phase 2b, randomized, double-blind, placebo-controlled study","volume":"87","author":"Tehlirian","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1111\/bjd.14399","article-title":"Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo-controlled phase IIa study","volume":"174","author":"Ludbrook","year":"2016","journal-title":"Br. J. Dermatol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/bjd\/ljad098","article-title":"Efficacy and safety of topical brepocitinib cream for mild-to-moderate chronic plaque psoriasis: A phase IIb randomized double-blind vehicle-controlled parallel-group study","volume":"189","author":"Landis","year":"2023","journal-title":"Br. J. Dermatol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.jaad.2011.12.018","article-title":"Preliminary clinical activity of a topical JAK1\/2 inhibitor in the treatment of psoriasis","volume":"67","author":"Punwani","year":"2012","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/bjd.13994","article-title":"Downmodulation of key inflammatory cell markers with a topical Janus kinase 1\/2 inhibitor","volume":"173","author":"Punwani","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/bjd.12266","article-title":"A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis","volume":"169","author":"Ports","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Papp, K.A., Bissonnette, R., Gooderham, M., Feldman, S.R., Iversen, L., Soung, J., Draelos, Z., Mamolo, C., Purohit, V., and Wang, C. (2016). Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: A Phase 2b randomized clinical trial. BMC Dermatol., 16.","DOI":"10.1186\/s12895-016-0051-4"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/bjd.16798","article-title":"Tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: Long-term safety and efficacy in an open-label extension study","volume":"179","author":"Valenzuela","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1016\/S2665-9913(21)00010-2","article-title":"Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: Final analysis of the OPAL Balance long-term extension study","volume":"3","author":"Nash","year":"2021","journal-title":"Lancet Rheumatol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1136\/annrheumdis-2019-216761","article-title":"Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data","volume":"79","author":"Mease","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Kristensen, L.E., Strober, B., Poddubnyy, D., Leung, Y.Y., Jo, H., Kwok, K., Vranic, I., Fleishaker, D.L., Fallon, L., and Yndestad, A. (2023). Association between baseline cardiovascular risk and incidence rates of major adverse cardiovascular events and malignancies in patients with psoriatic arthritis and psoriasis receiving tofacitinib. Ther. Adv. Musculoskelet. Dis., 15.","DOI":"10.1177\/1759720X221149965"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1136\/ard-2022-223715","article-title":"Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: An analysis of the open label, randomised controlled study ORAL Surveillance","volume":"82","author":"Kristensen","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/acr.23930","article-title":"Changes in Lipid Levels and Incidence of Cardiovascular Events Following Tofacitinib Treatment in Patients with Psoriatic Arthritis: A Pooled Analysis Across Phase III and Long-Term Extension Studies","volume":"71","author":"Gladman","year":"2019","journal-title":"Arthritis Care Res."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1016\/j.jaci.2021.11.001","article-title":"Molecular and clinical effects of selective tyrosine kinase 2 inhibition with deucravacitinib in psoriasis","volume":"149","author":"Catlett","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMoa2022516","article-title":"Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis","volume":"384","author":"McInnes","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Kaczmarska, A., Kwiatkowska, D., Skrzypek, K.K., Kowalewski, Z.T., Jaworecka, K., and Reich, A. (2023). Pathomechanism of Pruritus in Psoriasis and Atopic Dermatitis: Novel Approaches, Similarities and Differences. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241914734"},{"key":"ref_138","unstructured":"(2024, April 18). Pfizer Receives Complete Response Letter from FDA for Oral XELJANZ\u00ae (Tofacitinib Citrate) Supplemental New Drug Application for Moderate to Severe Chronic Plaque Psoriasis|Pfizer. Available online: https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer_receives_complete_response_letter_from_fda_for_oral_xeljanz_tofacitinib_citrate_supplemental_new_drug_application_for_moderate_to_severe_chronic_plaque_psoriasis."},{"key":"ref_139","unstructured":"European Medicine Agency (2024, April 18). EMA Confirms Measures to Minimise Risk of Serious Side Effects with Janus Kinase Inhibitors for Chronic Inflammatory Disorders. EMA\/27681\/2023. 27 January 2023. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/janus-kinase-inhibitors-jaki."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N. Engl. J. Med."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/9\/4681\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:33:11Z","timestamp":1760106791000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/9\/4681"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,25]]},"references-count":140,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["ijms25094681"],"URL":"https:\/\/doi.org\/10.3390\/ijms25094681","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,25]]}}}